tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2024-023tumors-1414Research ArticleКЛИНИЧЕСКИЕ СЛУЧАИCLINICAL NOTESТо, что скрыто от глаз. Проблема хронической и отсроченной токсичности на фоне иммунотерапии на примере клинических случаев и обзора литературыWhat is hidden from the view. The problem of chronic and delayed toxicity after immunotherapy based on clinical cases and literature reviewhttps://orcid.org/0009-0000-9717-1700СоболевМ. М.SobolevM. M.

Максим Михайлович Соболев

117152 Москва, Загородное шоссе, 18А

Maksim Mikhailovich Sobolev

18A Zagorodnoe Shosse, Moscow 117152

maxisobol94@gmail.comhttps://orcid.org/0000-0001-9864-3837ПокатаевИ. А.PokataevI. A.

Илья Анатольевич Покатаев

117152 Москва, Загородное шоссе, 18А

Ilya Anatolevich Pokataev

18A Zagorodnoe Shosse, Moscow 117152

https://orcid.org/0009-0007-2856-5176КузьминаЕ. С.KuzminaE. S.

Евгения Сергеевна Кузьмина

117152 Москва, Загородное шоссе, 18А

Evgeniya Sergeevna Kuzmina

18A Zagorodnoe Shosse, Moscow 117152

https://orcid.org/0000-0002-6619-6179ГалкинВ. Н.GalkinV. N.

Всеволод Николаевич Галкин

117152 Москва, Загородное шоссе, 18А

Vsevolod Nikolaevich Galkin

18A Zagorodnoe Shosse, Moscow 117152

Онкологический центр № 1 «Городской клинической больницы имени С.С. Юдина Департамента здравоохранения города Москвы»РоссияOncology Center No. 1 of the City Clinical Hospital named after S.S. Yudin of the Moscow Department of HealthRussian Federation2024181220241438691Copyright © Соболев М.М., Покатаев И.А., Кузьмина Е.С., Галкин В.Н., 20242024Соболев М.М., Покатаев И.А., Кузьмина Е.С., Галкин В.Н.Sobolev M.M., Pokataev I.A., Kuzmina E.S., Galkin V.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/1414

Появление иммунотерапии изменило подход к лечению ряда онкологических заболеваний. Пациенты, которые ранее были обречены на смерть в течение нескольких месяцев, в настоящий момент могут жить в течение многих лет. Тем не менее, у иммунотерапии есть свой спектр нежелательных явлений. Проблема токсичности на фоне иммунотерапии с каждым годом становится все более значимой. Особенностью нежелательных явлений иммунотерапии является то, что около 40% из них приобретают хронический характер, а часть может развиться через долгое время после завершения иммунотерапии. Учитывая то, что в последние годы в клинических рекомендациях появились опции с адъювантными режимами иммунотерапии, необходимо привлечь большее внимание к проблеме хронической и отсроченной иммуноопосредованной токсичности. В данной статье мы представляем клинические случаи, а также обзор литературы, посвященные данному типу нежелательных явлений.

The emergence of immunotherapy has revolutionized the treatment approaches of numerous malignancies. Patients that previously faced a prognosis of only a few months left to live can now enjoy extended lifespans for several years. Nevertheless, it is crucial to acknowledge that immunotherapy carries its own spectrum of adverse events. Notably, the issue of immune-related toxicity is progressively gaining prominence with each passing year. A distinctive feature of these immune-related adverse events is their propensity to transition into chronic conditions, with some manifesting long after discontinuation of immunotherapy. Given the current incorporation of adjuvant immunotherapy regimens in clinical guidelines, it becomes imperative to direct heightened attention towards the challenges associated with chronic and delayed toxicity of immunotherapy.

иммунотерапиятоксичностьонкологиянежелательные явлениякачество жизнинадпочечниковая недостаточностьтиреоидитimmunotherapytoxicityoncologyadverse eventsquality of lifeadrenal insufficiencythyreoiditisСтатья подготовлена без спонсорской поддержкиThe article was prepared without sponsorshipReferencesEggermont А.М.М., Blank C.U., Mandala М., et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 2018;378(19):1789-1801. https://doi.org/10.1056/NEJMoal802357Eggermont А.М.М., Blank C.U., Mandala М., et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 2018;378(19):1789-1801. https://doi.org/10.1056/NEJMoal802357Felip E., Altorki N., Zhou C., et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB — IIIA nonsmall-cell lung cancer (iMpowerOlO): arandomised, multicentre, open-label, phase 3 trial. Lancet 2021;398(10308):1344-1357. https://doi.org/10.1016/S0140-6736(21)02098-5Felip E., Altorki N., Zhou C., et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB — IIIA nonsmall-cell lung cancer (iMpowerOlO): arandomised, multicentre, open-label, phase 3 trial. Lancet 2021;398(10308):1344-1357. https://doi.org/10.1016/S0140-6736(21)02098-5Weber J.S., Poretta T., Stwalley B.D., et al. Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival. Cancer Immunol Immunother 2023;72(4):945-954. https://doi.org/10.1007/s00262-022-03302-5Weber J.S., Poretta T., Stwalley B.D., et al. Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival. Cancer Immunol Immunother 2023;72(4):945-954. https://doi.org/10.1007/s00262-022-03302-5Patrinely Jr J.R., Young A.C., Quach H., et al. Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand. Eur J Cancer 2020;135:211-220. https://doi.Org/10.1016/j.ejca.2020.05.005Patrinely Jr J.R., Young A.C., Quach H., et al. Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand. Eur J Cancer 2020;135:211-220. https://doi.Org/10.1016/j.ejca.2020.05.005PatrinelyJrJ.R., Johnson R., Lawless A.R., et al. Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma. JAMA Oncol 2021;7(5):744-748. https://doi.org/10.1001/jamaoncol.2021.0051PatrinelyJrJ.R., Johnson R., Lawless A.R., et al. Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma. JAMA Oncol 2021;7(5):744-748. https://doi.org/10.1001/jamaoncol.2021.0051Couey M.A., Bell R.B., Patel A.A., et al. Delayed immune-related events (DIRE) after discontinuation ofimmunotherapy: diagnostichazard ofautoimmunity at a distance. J Immunother Cancer 2019;7(l):165. https://doi.org/10.1186/s40425-019-0645-6Couey M.A., Bell R.B., Patel A.A., et al. Delayed immune-related events (DIRE) after discontinuation ofimmunotherapy: diagnostichazard ofautoimmunity at a distance. J Immunother Cancer 2019;7(l):165. https://doi.org/10.1186/s40425-019-0645-6Проценко C.A., Баллюзек М.Ф., Васильев Д.А. и соавт. Практические рекомендации по управлению иммуноопосредованными нежелательными явлениями. Злокачественные опухоли 2023;13(3s2):212-251. https://doi.org/10.18027/22245057-2023-13-3s2-2-212-251.Protsenko S.A., Ballyuzek M.F., Vasiliev D.A., et al. Practical recommendations for the management of immune-mediated adverse events. Zlokachestvennie opuholi = Malignant Tumors 2023;13(3s2):212-251 (In Russ.), https://doi.org/10.18027/22245057-2023-13-3s2-2-212-251Johnson D.B., Nebhan C.A., Moslehi J.J., Balko J.M. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol 2022;19(4):254-267. https://doi.org/10.1038/s41571-022-00600-wJohnson D.B., Nebhan C.A., Moslehi J.J., Balko J.M. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol 2022;19(4):254-267. https://doi.org/10.1038/s41571-022-00600-wGhisoni E., Wicky A., Bouchaab H., et al. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy. Eur J Cancer 2021;149:153-164. https://doi.Org/10.1016/j.ejca.2021.03.010Ghisoni E., Wicky A., Bouchaab H., et al. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy. Eur J Cancer 2021;149:153-164. https://doi.Org/10.1016/j.ejca.2021.03.010Tong J., Kartolo A., Yeung C., et al. Long-term toxicities of immune checkpoint inhibitor (ICI) in melanoma patients. Curr Oncol 2022;29(10):7953-7963. https://doi.org/10.3390/curroncol29100629Tong J., Kartolo A., Yeung C., et al. Long-term toxicities of immune checkpoint inhibitor (ICI) in melanoma patients. Curr Oncol 2022;29(10):7953-7963. https://doi.org/10.3390/curroncol29100629Parakh S., Cebon J., Klein O. Delayed autoimmune toxicity occurring several months after cessation of anti-PD-1 therapy. Oncologist 2018;23(7):849-851. https://doi.org/10.1634/theoncologist.2017-0531Parakh S., Cebon J., Klein O. Delayed autoimmune toxicity occurring several months after cessation of anti-PD-1 therapy. Oncologist 2018;23(7):849-851. https://doi.org/10.1634/theoncologist.2017-0531Owen C.N., Bai X., Quah T., et al. Delayed immune-related adverse events with anti-PD-l-based immunotherapy in melanoma. Ann Oncol 2021;32(7):917—925. https://doi.Org/10.1016/j.annonc.2021.03.204Owen C.N., Bai X., Quah T., et al. Delayed immune-related adverse events with anti-PD-l-based immunotherapy in melanoma. Ann Oncol 2021;32(7):917—925. https://doi.Org/10.1016/j.annonc.2021.03.204Jacob S., Quandt Z., Melisko M.E., et al. Delayed immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors. J Clin Oncol 2023. № 16_suppl (41). e24091. https://doi.org/10.1200/JCO.2023.41.16_suppl.e2409Jacob S., Quandt Z., Melisko M.E., et al. Delayed immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors. J Clin Oncol 2023. № 16_suppl (41). e24091. https://doi.org/10.1200/JCO.2023.41.16_suppl.e2409Chen Y.C., Jaffer M., Zhou L., et al. A brain, a heart, and the courage: balancing benefit and toxicity of immunotherapy in melanoma. Am Soc Clin Oncol Educ Book 2023;43:e390594. https://doi.org/10.1200/EDBK_390594Chen Y.C., Jaffer M., Zhou L., et al. A brain, a heart, and the courage: balancing benefit and toxicity of immunotherapy in melanoma. Am Soc Clin Oncol Educ Book 2023;43:e390594. https://doi.org/10.1200/EDBK_390594Kotwal A., Perlman J.E., Goldner W.S. Endocrine dysfunction from immune checkpoint inhibitors: pearls and pitfalls in evaluation and management. JCO Oncol Pract 2023;19(7):395-402. https://doi.org/10.1200/OP.23.00023.Kotwal A., Perlman J.E., Goldner W.S. Endocrine dysfunction from immune checkpoint inhibitors: pearls and pitfalls in evaluation and management. JCO Oncol Pract 2023;19(7):395-402. https://doi.org/10.1200/OP.23.00023.

The authors declare that there are no conflicts of interest present.